YAP调控肝癌细胞增殖并改变其对索拉非尼的敏感性
该研究检测了YAP在肝癌细胞株中的表达,并通过转染si-YAP或YAP过表达质粒观察其对增殖、细胞周期及索拉非尼敏感性的影响;裸鼠移植瘤实验显示敲低YAP联合索拉非尼组瘤重最低。结论认为YAP在肝癌细胞系中表达上调,影响增殖、细胞周期及索拉非尼敏感性,是肝癌治疗的潜在分子靶点。
要点
- YAP蛋白在肝癌细胞株中表达升高。
- 敲低YAP降低SK-Hep-1细胞存活率并增加G0/G1期细胞比例。
- 敲低YAP联合索拉非尼组裸鼠移植瘤瘤重最低。
核心结论
- YAP在肝癌细胞系中表达上调,其表达变化影响细胞增殖能力和细胞周期进程,并影响肝癌对索拉非尼的敏感性。
- YAP是肝癌治疗的一个潜在分子靶点。
研究设计与样本
- 采用Western blot检测人肝癌细胞株SMMC-7721、SK-Hep-1、HepG-2、Huh7和正常人肝细胞株L-O2中YAP蛋白表达水平。
- 以YAP的小干扰RNA或过表达质粒分别转染SK-Hep-1和Huh7细胞,采用CCK-8法检测细胞增殖能力,流式细胞术检测细胞周期。
- 将SK-Hep-1和SK-Hep-1 si-YAP细胞接种于裸鼠皮下,并以索拉非尼灌胃,观察移植瘤与对照组的差异。
主要发现
- 下调SK-Hep-1细胞YAP表达后,细胞存活率为(78.5±0.3)%,低于对照组(92.3±0.2)%,P=0.025;G0/G1期细胞占(65.4±3.3)%,高于对照组(55.7±3.4)%,P=0.039。
- 上调Huh7细胞YAP表达后,细胞存活率为(81.2±1.3)%,高于对照组(62.5±1.1)%,P=0.013;G0/G1期细胞占(38.2±3.8)%,低于对照组(48.8±2.9)%,P=0.019。
- si-YAP联合索拉非尼组SK-Hep-1细胞存活率为(31.13±1.79)%,低于索拉非尼单药组(48.87±0.58)%,P=0.001;过表达YAP联合索拉非尼组Huh7细胞存活率为(69.98±2.94)%,高于索拉非尼单药组(53.53±1.93)%,P=0.001。
- SK-Hep-1组、索拉非尼单药组、SK-Hep-1 si-YAP组和SK-Hep-1 si-YAP联合索拉非尼组瘤重分别为(0.96±0.08)g、(0.62±0.08)g、(0.70±0.06)g和(0.27±0.02)g;索拉非尼单药组和SK-Hep-1 si-YAP组瘤重均低于SK-Hep-1组,P分别为0.012和0.031;SK-Hep-1 si-YAP联合索拉非尼组瘤重低于SK-Hep-1 si-YAP组,P=0.001。
临床怎么用
- 原文结论未据此给出临床推荐,仅指出YAP是肝癌治疗的一个潜在分子靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To detect the expression level of YES-associated protein 1 (YAP) in hepatocellular carcinoma (HCC) cell lines and investigate its effects on the proliferation activity and the sensitivity to sorafenib in HCC cells. Methods: Western blot was used to detect the protein expression levels of YAP in SMMC-7721, SK-Hep-1, HepG-2, Huh7 and the normal liver cell line L-O2. YAP specific small interfering RNA (si-YAP) or YAP expression plasmid were transfected in SK-Hep-1 or Huh7 cells, respectively. Cell counting kit-8 (CCK-8) test was used to detect the cell proliferation activity and the cell cycle test was conducted by flow cytometry. SK-Hep-1 and SK-Hep-1 si-YAP cells were subcutaneously injected into the nude mice which were sequentially treated by intragastric administration of sorafenib, and the tumor growth in vivo were observed and compared. Results: The expression of YAP was upregulated in HCC cell lines. Deletion of YAP expression significantly decreased the survival rate of SK-Hep-1 cells [(78.5±0.3)% vs (92.3±0.2)%, P=0.025]. Knockdown of YAP significantly increased the percentage of G(0)/G(1)-phase cells [ (65.4±3.3) % vs (55.7±3.4) %, P=0.039]. On the contrary, upregulation of the YAP expression in Huh7 cells significantly increased the cell survival rate [(81.2±1.3)% vs (62.5±1.1)%, P=0.013] and reduced the percentage of G(0)/G(1)-phase cells [(38.2±3.8)% vs (48.8±2.9)%, P=0.019]. The survival rate of SK-Hep-1 cells treated by si-YAP combined with sorafenib was (31.13±1.79)%, significantly lower than (48.87±0.58) % of SK-Hep-1 cells treated by sorafenib alone (P=0.001), while overexpression of YAP attenuated the inhibitory effect of sorafenib on the survival of Huh7 cells [(69.98±2.94) % vs (53.53±1.93)%, P=0.001]. The tumor weights of SK-Hep-1 group, sorafenib alone group, SK-Hep-1 si-YAP group and SK-Hep-1 si-YAP combined with sorafenib group were (0.96±0.08) g, (0.62±0.08) g, (0.70±0.06) g and (0.27±0.02) g, respectively. The tumor weights of sorafenib alone group and SK-Hep-1 si-YAP group were significantly lower than that of SK-Hep-1 group (P=0.012 and P=0.031, respectively). The tumor weight of SK-Hep-1 si-YAP combined with sorafenib group was significantly lower than that of SK-Hep-1 si-YAP group (P=0.001). Conclusions: The expression of YAP is upregulated in HCC cell lines, which regulates the proliferation, cell cycle, and sensitivity to sorafenib of HCC cells. YAP is a potential molecular target for HCC treatment. 目的: 检测YAP在肝癌细胞中的表达水平,并探讨其对肝癌细胞增殖活性以及对索拉非尼敏感性的影响。 方法: 采用Western blot方法检测人肝癌细胞株SMMC-7721、SK-Hep-1、HepG-2、Huh7和正常人肝细胞株L-O2中YAP的蛋白表达水平。以YAP的小干扰RNA或过表达质粒分别转染SK-Hep-1和Huh7细胞,采用细胞计数试剂盒8(CCK-8)法检测细胞的增殖能力,流式细胞术检测细胞周期。将SK-Hep-1和SK-Hep-1 si-YAP细胞接种于裸鼠皮下,并以索拉非尼灌胃,观察移植瘤与对照组的差异。 结果: YAP蛋白在肝癌细胞株中表达升高。下调SK-Hep-1细胞的YAP表达后,细胞存活率为(78.5±0.3)%,与对照组[(92.3±0.2)%]比较明显下降,差异有统计学意义(P=0.025);G(0)/G(1)期细胞占(65.4±3.3)%,与对照组[(55.7±3.4)%]比较明显升高,差异有统计学意义(P=0.039)。上调Hun7细胞的YAP表达后,细胞存活率为(81.2±1.3)%,与对照组[(62.5±1.1)%]比较明显升高,差异有统计学意义(P=0.013); G(0)/G(1)期细胞占(38.2±3.8)% ,与对照组[(48.8±2.9)%]比较明显下降,差异有统计学意义(P=0.019)。si-YAP+索拉非尼组SK-Hep-1细胞的存活率为(31.13±1.79)%,低于索拉非尼组[(48.87±0.58)%],差异有统计学意义(P<0.0001)。PC3.1-YAP+索拉非尼组的细胞存活率为(69.98±2.94)%,高于索拉非尼组[(53.53±1.93)%],差异有统计学意义(P<0.0001)。裸鼠移植瘤模型实验显示,SK-Hep-1组、SK-Hep-1+索拉非尼组、SK-Hep-1 si-YAP组和SK-Hep-1 si-YAP+索拉非尼组瘤重分别为(0.96±0.08)g、(0.62±0.08)g、(0.70±0.06)g和(0.27±0.02)g。SK-Hep-1+索拉非尼组和SK-Hep-1 si-YAP组瘤重均低于SK-Hep-1组(P值分别为0.012和0.031),SK-Hep-1 si-YAP+索拉非尼组瘤重低于SK-Hep-1 si-YAP组(P=0.001)。 结论: YAP在肝癌细胞系中表达上调,其表达变化影响细胞增殖能力和细胞周期进程,并影响肝癌对索拉非尼的敏感性。YAP是肝癌治疗的一个潜在分子靶点。.
引用
- Guo LW, Shao GL, Luo J, et al. [YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 30481931. doi:10.3760/cma.j.issn.0253-3766.2018.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。